266 related articles for article (PubMed ID: 12774067)
21. [Vaccines against HIV].
Holm-Hansen C
Tidsskr Nor Laegeforen; 2006 Nov; 126(23):3117-20. PubMed ID: 17160118
[TBL] [Abstract][Full Text] [Related]
22. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
[TBL] [Abstract][Full Text] [Related]
23. The immune response to AIDS virus infection: good, bad, or both?
Deeks SG; Walker BD
J Clin Invest; 2004 Mar; 113(6):808-10. PubMed ID: 15067312
[TBL] [Abstract][Full Text] [Related]
24. Forecasting the future of HIV epidemics: the impact of antiretroviral therapies & imperfect vaccines.
Blower S; Schwartz EJ; Mills J
AIDS Rev; 2003; 5(2):113-25. PubMed ID: 12876900
[TBL] [Abstract][Full Text] [Related]
25. Functional patterns of HIV-1-specific CD4 T-cell responses in children are influenced by the extent of virus suppression and exposure.
Correa R; Harari A; Vallelian F; Resino S; Munoz-Fernandez MA; Pantaleo G
AIDS; 2007 Jan; 21(1):23-30. PubMed ID: 17148964
[TBL] [Abstract][Full Text] [Related]
26. HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine.
Gilbert PB; Ackers ML; Berman PW; Francis DP; Popovic V; Hu DJ; Heyward WL; Sinangil F; Shepherd BE; Gurwith M
J Infect Dis; 2005 Sep; 192(6):974-83. PubMed ID: 16107949
[TBL] [Abstract][Full Text] [Related]
27. Down-regulation of interleukin-7 receptor (CD127) in HIV infection is associated with T cell activation and is a main factor influencing restoration of CD4(+) cells after antiretroviral therapy.
Benito JM; López M; Lozano S; González-Lahoz J; Soriano V
J Infect Dis; 2008 Nov; 198(10):1466-73. PubMed ID: 18847371
[TBL] [Abstract][Full Text] [Related]
28. The prospects for vaccines against HIV-1: more than a field of long-term nonprogression?
Sheppard N; Sattentau Q
Expert Rev Mol Med; 2005 Feb; 7(2):1-21. PubMed ID: 15710051
[TBL] [Abstract][Full Text] [Related]
29. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
[TBL] [Abstract][Full Text] [Related]
30. [CD4 lymphocytes as targets and actors in the pathogenesis of HIV infection--therapeutic implications].
Theze J
Bull Acad Natl Med; 2008 Oct; 192(7):1453-66; discussion 1466-8. PubMed ID: 19445368
[TBL] [Abstract][Full Text] [Related]
31. [HIV infection: in the HAART era, CD4 makes the difference].
Varsky C
Acta Gastroenterol Latinoam; 2004; 34(3):117-9. PubMed ID: 15742925
[No Abstract] [Full Text] [Related]
32. CD4 lymphocyte percentage versus absolute CD4 lymphocyte count in predicting HIV disease progression: an old debate revisited.
Goicoechea M; Haubrich R
J Infect Dis; 2005 Sep; 192(6):945-7. PubMed ID: 16107944
[No Abstract] [Full Text] [Related]
33. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope.
Emini EA; Koff WC
Science; 2004 Jun; 304(5679):1913-4. PubMed ID: 15218131
[No Abstract] [Full Text] [Related]
34. Rebuilding the immune system.
Averitt D
WORLD; 1999 Apr; (No 96):1-2. PubMed ID: 11366944
[TBL] [Abstract][Full Text] [Related]
35. Delayed progression to AIDS in volunteers treated with long-term HIV-1 Immunogen (REMUNE) therapy in Thailand.
Chantratita W; Sukeepaisarncharoen W; Chandeying V; Kulpradist S; Israngkura Na Ayudhtaya B; Rugpao S; Sirawaraporn W; Boonshuyar C; Churdboonchart V
HIV Med; 2004 Sep; 5(5):317-25. PubMed ID: 15369506
[TBL] [Abstract][Full Text] [Related]
36. The value of preserving HIV-specific immune responses.
Kaufmann DE; Rosenberg ES
J HIV Ther; 2003 Feb; 8(1):19-25. PubMed ID: 12840711
[TBL] [Abstract][Full Text] [Related]
37. Use of total lymphocyte count for monitoring response to antiretroviral therapy.
Schreibman T; Friedland G
Clin Infect Dis; 2004 Jan; 38(2):257-62. PubMed ID: 14699459
[TBL] [Abstract][Full Text] [Related]
38. Restoration of CD4 T-cell responses to cytomegalovirus is short-lived in severely immunodeficient HIV-infected patients responding to highly active antiretroviral therapy.
Keane NM; Price P; Lee S; Almeida CA; Stone SF; James I; French MA
HIV Med; 2004 Nov; 5(6):407-14. PubMed ID: 15544692
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects.
Fernandez-Cruz E; Moreno S; Navarro J; Clotet B; Bouza E; Carbone J; Peña JM; Pérez Molina J; Podzamczer D; Rubio R; Ocaña I; Pulido F; Viciana P; Maradona JA; Blazquez R; Barros C; Quereda C; Rodriguez-Sainz C; Gil J; Abad ML; Díaz L; Cantó C; Muñoz MA; Ferrer E; Jou A; Sirera G; Díaz M; Lopez F; Gatell JM; Gonzalez-Lahoz J;
Vaccine; 2004 Aug; 22(23-24):2966-73. PubMed ID: 15297045
[TBL] [Abstract][Full Text] [Related]
40. Mapping the future of HIV vaccines.
Nabel GJ
Nat Rev Microbiol; 2007 Jul; 5(7):482-4. PubMed ID: 17571457
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
